These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35968876)

  • 81. Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy.
    Ciarlitto C; Vittucci AC; Antilici L; Concato C; Di Camillo C; Zangari P; Villani A
    Ital J Pediatr; 2019 Aug; 45(1):115. PubMed ID: 31462274
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
    Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
    Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies.
    Lanari M; Anderson EJ; Sheridan-Pereira M; Carbonell-Estrany X; Paes B; Rodgers-Gray BS; Fullarton JR; Grubb E; Blanken M
    Epidemiol Infect; 2020 Aug; 148():e170. PubMed ID: 32799945
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan.
    Nagasawa K; Ishiwada N
    J Infect Chemother; 2022 Feb; 28(2):146-157. PubMed ID: 34952776
    [TBL] [Abstract][Full Text] [Related]  

  • 89. An outbreak of RSV infections in a neonatology clinic during the RSV-season.
    Vakrilova L; Nikolova SH; Slavov S; Radulova P; Slancheva B
    BMC Pediatr; 2021 Dec; 21(1):567. PubMed ID: 34895173
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
    Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
    J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis].
    Grimaldi M; Cornet B; Milou C; Gouyon JB
    Arch Pediatr; 2002 Jun; 9(6):572-80. PubMed ID: 12108310
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
    Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
    Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
    Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
    J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Hospital Admission Trends for Bronchiolitis in Scotland, 2001-2016: A National Retrospective Observational Study.
    Chung A; Reeves RM; Nair H; Campbell H;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S592-S598. PubMed ID: 32794556
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus.
    van Wijhe M; Johannesen CK; Simonsen L; Jørgensen IM; ; Fischer TK
    J Infect Dis; 2022 Aug; 226(Suppl 1):S55-S62. PubMed ID: 35426942
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A data linkage modelling study.
    Reeves RM; Hardelid P; Panagiotopoulos N; Minaji M; Warburton F; Pebody R
    J Infect; 2019 Jun; 78(6):468-475. PubMed ID: 30817978
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
    Do LAH; Vodicka E; Nguyen A; Le TNK; Nguyen TTH; Thai QT; Pham VQ; Pham TU; Nguyen TN; Mulholland K; Cao MT; Le NTN; Tran AT; Pecenka C
    BMC Infect Dis; 2023 Feb; 23(1):73. PubMed ID: 36747128
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
    Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.